Who Paid My Doc
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer
Research payments
$3,851,981
Through program year 2025, $3,851,981 in research payments was reported against a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer, across 64 payments.
- Paid by (largest first)
- AstraZeneca Pharmaceuticals LP; AstraZeneca UK Limited
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $3,851,981 | 64 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- George Riosperez Columbus, OH Named on 3 payments
- Iyad Hamarneh Prescott, AZ Named on 3 payments
- Mamta Choksi Trinity, FL Named on 3 payments
- Vinni Juneja Silver Spring, MD Named on 3 payments
- Robert Jotte Lone Tree, CO Named on 3 payments
- Barry Berman West Palm Beach, FL Named on 3 payments
- Joseph Potz Horsham, PA Named on 3 payments
- Lalit Aneja North Venice, FL Named on 3 payments
- Roy Webb Hot Springs, AR Named on 3 payments
- Bharathi Muthusamy Indianapolis, IN Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.